Mr. Jacek Antas reports

HELIX BIOPHARMA CORP. ANNOUNCES PRIVATE PLACEMENT OF COMMON SHARES

Helix BioPharma Corp. has arranged a private placement financing of 12,766,667 common shares of the company at a price of 15 cents per common share for gross proceeds of $1,915,000.

The company intends to use the net proceeds of the private placement for working capital. The offering is subject to customary closing conditions, including the receipt of all necessary corporate and regulatory approvals, including the approval of the Toronto Stock Exchange. The common shares will be subject to a hold period of four months and one day from the closing date in accordance with applicable securities laws. In connection with the closing, the company will pay a cash fee of 10 per cent of gross proceeds raised to an eligible finder.

About Helix BioPharma Corp.

Helix BioPharma is a clinical-stage biopharmaceutical company developing unique therapies in the field of immune-oncology for the prevention and treatment of cancer based on its proprietary technological platform, DOS47. Helix BioPharma is listed on the Toronto Stock Exchange under the symbol HBP.

We seek Safe Harbor.